Who are Du-Cotecxin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): heparin + clopidogrel + aspirin, Nafamostat Mesilate, Heparin & aspirin, Plasma-derived antithrombin, Pradaxa, Coumadin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/du-cotecxin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Du-Cotecxin — Competitive Intelligence Brief

Du-Cotecxin (Du-Cotecxin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant. Area: Cardiovascular.

phase 2 Anticoagulant Thrombin, Factor Xa Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Du-Cotecxin (Du-Cotecxin) — London School of Hygiene and Tropical Medicine. Du-Cotecxin is a heparin-based anticoagulant.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Du-Cotecxin TARGET	Du-Cotecxin	London School of Hygiene and Tropical Medicine	phase 2	Anticoagulant	Thrombin, Factor Xa
heparin + clopidogrel + aspirin	heparin + clopidogrel + aspirin	Centre Hospitalier de PAU	marketed	Antiplatelet and anticoagulant combination	Thrombin, Factor Xa, Cyclooxygenase, P2Y12 receptor
Nafamostat Mesilate	Nafamostat Mesilate	Chong Kun Dang Pharmaceutical	marketed	Serine protease inhibitor	Serine proteases (thrombin, factor Xa, kallikrein, trypsin)
Heparin & aspirin	Heparin & aspirin	Dr.Vandana Bansal	phase 3	Anticoagulant and antiplatelet combination	Thrombin, Factor Xa, COX-1
Plasma-derived antithrombin	Plasma-derived antithrombin	Kyowa Kirin Co., Ltd.	phase 3	Anticoagulant	Thrombin, Factor Xa
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	marketed	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant class)

Fresenius Kabi · 4 drugs in this class
University of Sao Paulo · 3 drugs in this class
Beijing Anzhen Hospital · 2 drugs in this class
San Filippo Neri General Hospital · 2 drugs in this class
Yong Seog Oh · 2 drugs in this class
CCRF Consulting Co., Ltd. · 1 drug in this class
Boston Scientific Corporation · 1 drug in this class
Beijing Suncadia Pharmaceuticals Co., Ltd · 1 drug in this class
Faculty Hospital Kralovske Vinohrady · 1 drug in this class
Deutsches Herzzentrum Muenchen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Du-Cotecxin — Competitive Intelligence Brief. https://druglandscape.com/ci/du-cotecxin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab